Freezor 207Fl,207F3,207F5, Freezor Xtra 217Fl,217F3,217F5
Medtronic Cryocath, LP · Decision date Apr 23, 2026
What did the FDA approve?
FDA records P020045/S113 as a supplement to PMA P020045, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 23, 2026.
FDA approval order statement
approval for Freezor Coaxial Connector Adhesive Modifications
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 23, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P020045/S113
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Cryocath, LP
- Product code
- LPB
- Decision code
- APPR
- Decision date
- Apr 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cardiac ablation percutaneous catheter.
- Applicant
- Medtronic Cryocath, LP
- Product code
- LPB
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P020045/S113 received
Application receipt date recorded by FDA.
P020045/S113 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P020045. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code LPB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA | |
| Irvine Biomedical, Inc. | PMA supplement | Sep 3, 2026 | FDA | |
Ampere GeneratorP040014/S051 | Irvine Biomedical, Inc. | PMA supplement | Aug 7, 2026 | FDA |
Ampere GeneratorP960016/S094 | St Jude Medical | PMA supplement | Aug 7, 2026 | FDA |
MAGiC Ablation CatheterP240014/S001 | Stereotaxis, Inc. | PMA supplement | Jul 31, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Cryocath, LP
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St., Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P020045/S113
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

